Publications by authors named "Ludwike van Kalmthout"
Introduction: Prostate specific membrane antigen (PSMA) directed radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC) patients. However, it is still poorly understood why approximately 40% of the patients does not respond to PSMA-RLT. The aims of this study were to evaluate the pretreatment PSMA expression on immunohistochemistry (IHC) and PSMA uptake on PET/CT imaging in mCRPC patients who underwent PSMA-RLT.
View Article and Find Full Text PDFArticle Synopsis
- PSMA PET/CT has high specificity but low sensitivity (40-50%) for detecting pelvic lymph node metastases in prostate cancer, meaning a negative result doesn't rule out metastases.
- * The study compares a new PSMA PET/CT-based treatment planning approach against traditional methods, focusing on costs and quality of life over a lifetime.
- * The findings suggest that while using PSMA PET/CT saves about €674 per patient, it can lead to a slight decrease in quality of life because of false positive results that misclassify patients needing curative treatment as having advanced disease.
Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
Eur J Nucl Med Mol Imaging
September 2022
Article Synopsis
- F-PSMA-1007 is a radiotracer for prostate cancer staging that lacks large validation studies for its diagnostic accuracy compared to traditional methods like histopathology.
- A trial evaluated 99 men with intermediate to high-risk prostate cancer, measuring the sensitivity and specificity of F-PSMA-1007 PET/CT against lymph node dissection results.
- The results indicated high specificity (89.9%) but moderate sensitivity (53.3%), suggesting that while it’s effective for certain detections, it shouldn’t replace extensive surgical procedures for accurate staging.
Purpose: Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) is a novel treatment for castration-resistant prostate cancer (mCRPC). While the majority of patients responds to PSMA-RLT, with 10-15% having an exceptional response, approximately 30% of patients is unresponsive to PSMA-RLT. The molecular underpinning may in part explain these varying responses.
View Article and Find Full Text PDFPurpose: Prospective validation of Ga prostate specific membrane antigen positron emission tomography/computerized tomography is lacking in initial staging of prostate cancer. In this study we evaluated the diagnostic accuracy of Ga prostate specific membrane antigen positron emission tomography/computerized tomography for detecting lymph node metastasis in patients with intermediate-high risk prostate cancer.
Materials And Methods: Patients with newly diagnosed prostate cancer and negative bone scan findings at greater than 10% MSKCC (Memorial Sloan Kettering Cancer Center) risk for lymph node metastasis were prospectively included in study from October 2017 to October 2018.
Purpose: The present study summarizes the first experience with Lu-PSMA-617 (Lu-PSMA) treatment in metastatic castration-resistant prostate cancer (PCa) in our institution.
Methods: This was an analysis of the first 30 consecutive patients who underwent Lu-PSMA therapy. Biochemical response was defined as prostate-specific antigen decrease of 50% or greater.
This report describes a case of a 54-year-old man who underwent lutetium-177-PSMA therapy in the setting of metastatic castration-resistant prostate cancer (mCRPC) in the University Medical Center Utrecht. Following administration of the second cycle, patient presented with a slowly impairing, bilateral visual loss. This clinical presentation was most likely the result of the high intracranial pressure due to impediment of cerebrospinal fluid circulation, possibly related to obstructive dural thickness, being either caused by dural and/or leptomeningeal metastases of advanced mCRPC or by local radiation effects following lutetium-177-PSMA therapy.
View Article and Find Full Text PDFBackground: External cooling of the salivary glands is advised to prevent xerostomia in lutetium-177-PSMA treatment for advanced prostate cancer. Since evidence addressing this subject is sparse, this study aims to determine impact of icepacks application on uptake in salivary glands. Eighty-nine patients referred for gallium-68-PSMA PET/CT for (re)staging of prostate cancer were prospectively included.
View Article and Find Full Text PDFImportance: Although current guidelines recommend cochlear implantation only for children with profound hearing impairment (HI) (>90 decibel [dB] hearing level [HL]), studies show that children with severe hearing impairment (>70-90 dB HL) could also benefit from cochlear implantation.
Objective: To perform a systematic review to identify audiologic thresholds (in dB HL) that could serve as an audiologic candidacy criterion for pediatric cochlear implantation using 4 domains of speech and language development as independent outcome measures (speech production, speech perception, receptive language, and auditory performance).
Evidence Review: PubMed and Embase databases were searched up to June 28, 2017, to identify studies comparing speech and language development between children who were profoundly deaf using cochlear implants and children with severe hearing loss using hearing aids, because no studies are available directly comparing children with severe HI in both groups.